



27-December-2013

Patrick McLaughlin
Executive Director
Anaheim Clinical Trials
1085 N. Harbor Blvd.
Anaheim, CA 92801

RE: Protocol NP27946: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Ritonavir-Boosted DANOPREVIR and RO5024048 in Different Combinations in Null Responder or Treatment-Naive Patients with Chronic Hepatitis C and Compensated Cirrhosis

Dear Mr. McLaughlin:

As 2013 is coming to an end, I just wanted to write you a quick letter of appreciation regarding the performance of Anaheim Clinical Trials, Dr. Michael DeMicco and Michelle Haynes in the conduct of the above mentioned protocol. Your site was one of the two sites identified early on in the start-up process for your expertise in the therapeutic area and your ability to provide all the required regulatory and financial documentation in an expedient manner. I remember speaking to both Dr. DeMicco and Michelle at the Investigator's Meeting for this study, where they promised they'd be able to enroll the first subject into this study; and sure enough, they were good to their word. Being the first site to enroll a subject into a study is always a challenge, and both Dr. DeMicco and Michelle were able to provide us with helpful feedback that we were able to pass along to other sites as they enrolled their first subjects.

During the course of the study, both Dr. DeMicco and Michelle always ensured they followed the protocol, and if they were ever in doubt, they always ensure they followed up with PRA or our Medical Monitor first. It was apparent that they took the well-being of the subject enrolled as a top priority. During the course of the study, they were always very quick to respond to any questions or queries we asked of them, and they always provided us with high quality data and responses.

In closing, it has been a great pleasure working with Anaheim Clinical Trials, Dr. DeMicco and Michelle on this study, and I look forward to working with them again!

Kind Regards,

A handwritten signature in black ink, appearing to read 'C. Verf'.

Christopher Verf
Clinical Team Manager
PRA International